The BeiGene sponsored Satellite Symposium at the EHA2023 Hybrid Congress provided an overview of current advances in, and future approaches to, the management of patients with treatment-naïve (TN) or relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) using BTK inhibitors (BTKi), such as zanubrutinib in the ALPINE and SEQUOIA clinical trials, and Bcl-2 inhibitors (Bcl-2i). The speakers referenced new treatment guidelines as well as patient and therapy characteristics such as fit vs unfit patients in the era of targeted therapies, continuous vs fixed duration therapy, and monotherapy vs combination therapy. The Satellite Symposium included patient cases to illustrate how patient and disease characteristics inform treatment selection and sequencing. A summary of approaches using non-covalent BTKis, BTK degraders, and next-generation Bcl-2 inhibitors, with the goal of further improving outcomes for CLL patients, was also presented.

Please note that this video is a recording of a live session which took place during EHA2023.